Novartis (ADR)

NVS expects sales to witness a CAGR of 6% during 2023-2028, up from the earlier projection of 5%. The company acquires Kate Therapeutics to strengthen its portflio of gene therapies.» Mehr auf zacks.com

Jinda Noipho Performance Data Average Annual Total Returns 4(%) 1 Mth 3 Mths 1 Year 3 Year 5 Year 10 Year Since Inception Inception Date Class C (MUTF:LMGEX) - With Sales Charges a -1.46 4.15 21.61 5.98 7.49 4.70 4.22 02/17/1995 Class C - Without Sales Charges a -0.47 5.15 22.61 5.98 7.49 4.70 4.22 02/17/1995 Class A - With Sales Charges a -5.86 -0.42 16.85 4.77 7.09 4.90 6.80 02/03/2009 Class A - Without Sales Charges a -0.37 5.38 23.66 6.86 8.37 5.52 7.20 02/03/2009 MSCI EAFE Index-NR 0.92 7.26 24.77 5.48 8.20 5.71 - - Click to enlarge Share Class Details Sales Charges Expenses CUSIP Ticker Max CDSC Gross Net Class A 524686292 LMEAX 5.50% - 1.32% 1.28% Class C 524686284 LMGEX - 1.00% 2.17% 2.05% Click to enlarge Performance data quoted represents past performance, which does not guarantee future results. Current performance may be lower or higher than the figures shown. Principal value and investment returns will fluctuate, and investors' shares, when redeemed, may be worth more or less than the original cost. Performance would have been lower if fees had not been waived in various periods. Total returns assume the reinvestment of all distributions and the deduction of all fund expenses. Returns with sales charge reflect a deduction of the stated maximum sales charge. Returns for periods of less than one year are not annualized. All classes of shares may not be available to all investors or through all distribution channels. For current month-end performance, please call Franklin Templeton at (800) DIAL BEN/(800) 342-5236 or visit www.franklintempleton.com. An investor cannot invest directly in an index, and unmanaged index returns do not reflect any fees, expenses or sales charges. Net Returns ('NR') include income net of tax withholding when dividends are paid. The MSCI EAFE Index is a free float-adjusted market capitalization-weighted index designed to measure developed market equity performance, excluding the U.S. and Canada. Source: MSCI makes no warranties and shall have no liability with respect to any MSCI data reproduced herein. No further redistribution or use is permitted. This report is not prepared or endorsed by MSCI. Click to enlarge Performance Review Global equities ended the third quarter of 2024 collectively higher as they recovered from bouts of heightened volatility, including a market selloff in early August following an interest-rate hike by the Bank of Japan, as well as the release of a weaker-than-expected employment report in the United States, which led to recession fears. However, stock markets rebounded as resilient economic reports and a continued disinflation trend reignited hopes for an economic soft landing. Interest-rate cuts by the European Central Bank (ECB), the People's Bank of China (PBoC) and other central banks further bolstered equities worldwide. On the economic front, global manufacturing activity contracted for the third consecutive month in September, while flash reports for the same month indicated services activity continued to expand across regions. In this environment, the MSCI EAFE Index of stocks returned 7.26% in US-dollar terms. Quarterly Key Performance Drivers Regions Sectors HELPED KONAMI Group Corporation (OTCPK:KNAMF) Japan Industrials (Stock Selection) Chugai Pharmaceutical Co., Ltd. (chcgf) European Banks (Stock Selection and Overweight) Shell Plc (SHEL) Japan Communication Services (Stock Selection) HURT Novo Nordisk A/S Class B (NVO) European Health Care (Stock Selection) Mazda Motor Corp. (OTCPK:MZDAY) Developed Asia ex Japan (Underweight) ASML Holding NV (ASML) Japan Consumer Discretionary (Stock Selection) Click to enlarge The fund underperformed the benchmark for the third quarter of 2024. Stock selection results were mixed across regions and was negative overall, especially in continental Europe where the health care sector was notably weak. Stock selection was more moderately negative in the smaller markets of Australia, New Zealand & Canada, and Developed Asia ex Japan. Selection added meaningful value in Japan, led by industrials and communication services, and in the United Kingdom. Allocation decisions detracted, due primarily to an underweight in Developed Asia ex Japan, which outperformed within the benchmark for the quarter. An allocation to emerging markets, which is not in the benchmark, also detracted. Our diversified 1, multifactor stock selection model results were negative for the quarter, led down by the sentiment and alternative dimensions. The quality and value dimensions had little impact. At quarter-end, the portfolio was attractively valued with a lower 12-month forward price-to-earnings ratio 2 than the benchmark. The portfolio was well diversified across regions and sectors when compared to the benchmark. At the region level, the largest overweight was to the United Kingdom, and the largest underweight was to the developed Asia ex Japan. Sector allocations were close to the benchmark, with a modest overweight to information technology and underweight to financials. Outlook & Strategy The outlook for global equities continues to improve, helped by a continued disinflation trend in major developed markets. We believe the probability of a recession in the United States is remote amid ongoing economic resilience, although we continue to be wary of elevated equity valuations. Interest-rate cuts by the Fed 3, ECB, PBoC and other central banks have bolstered equities worldwide. Summer market volatility tested investor conviction, but fundamentals prevailed and stocks quickly rebounded. In the near term we may see continued volatility in reaction to Central bank actions, as well as the impact of the US election. While we expect to see further interest-rate cuts, the expectation of these cuts may be fully reflected in current prices. Against this background, we are confident that investors will continue to reward stocks that are attractively valued and invest in companies that have solid growth prospects and the ability to generate cash for their shareholders. We believe that our well-diversified, disciplined strategy will serve investors well in this environment. Portfolio Diversification Top Holdings % Novo Nordisk A/S (NVO) 2.71 ASML Holding NV (ASML) 2.16 Novartis AG (NVS) 1.88 SAP SE (SAP) 1.56 Roche Holding AG (OTCQX:RHHBY) 1.47 Allianz SE (OTCPK:ALIZF) 1.18 Hitachi Ltd (OTCPK:HTHIY) 1.14 UniCredit SpA (OTCPK:UNCFF) 1.11 Nestle SA (OTCPK:NSRGY) 1.06 Deutsche Telekom AG (OTCQX:DTEGY) 1.05 Click to enlarge Footnotes 1 Diversification does not assure a profit or protect against loss. It is possible to lose money in a diversified portfolio. 2 Forward price to earnings (forward P/E) is a measure of the price-to-earnings (P/E) ratio using forecasted earnings for the P/E calculation. 3 The Federal Reserve ("Fed") is responsible for the formulation of policies designed to promote economic growth, full employment, stable prices, and a sustainable pattern of international trade and payments. 4 Periods shorter than one year are shown as cumulative total returns. Not FDIC Insured | No Bank Guarantee | May Lose Value Inception Date 12/31/1992 Benchmark MSCI EAFE Index-NR Click to enlarge Fund Details Fund Description Seeks maximum long-term total return by investing primarily in non-U.S. stocks. Uses a quantitative process that assesses stocks by relative attractiveness based on a variety of measures including value, cash flow, earnings growth and sentiment. Region, country and sector allocations are based on rankings generated by the subadviser's proprietary models. May invest up to 35% of its total assets in emerging markets. Investment Team Chris Floyd, CFA Years with Firm 24 Years Experience 25 Sundaram Chettiappan, CFA Years with Firm 5 Years Experience 18 Chandra Seethamraju, Ph.D. Years with Firm 11 Years Experience 24 Click to enlarge What Are The Risks? All investments involve risks, including possible loss of principal. Equity securities are subject to price fluctuation and possible loss of principal. International investments are subject to special risks, including currency fluctuations and social, economic and political uncertainties, which could increase volatility. These risks are magnified in emerging markets. Active and frequent trading may increase a shareholder's tax liability and transaction costs. To the extent the portfolio invests in a concentration of certain securities, regions or industries, it is subject to increased volatility. Derivative instruments can be illiquid, may disproportionately increase losses, and have a potentially large impact on performance. These and other risks are discussed in the fund's prospectus. Important Information The information provided is not a complete analysis of every material fact regarding any country, market, industry, security or fund. Because market and economic conditions are subject to change, comments, opinions and analyses are rendered as of the date of this material and may change without notice. A portfolio manager's assessment of a particular security, investment or strategy is not intended as individual investment advice or a recommendation or solicitation to buy, sell or hold any security or to adopt any investment strategy; it is intended only to provide insight into the fund's portfolio selection process. Holdings are subject to change. Before investing, carefully consider a fund's investment objectives, risks, charges and expenses. You can find this and other information in each prospectus, or summary prospectus, if available, at www.franklintempleton.com. Please read it carefully. Franklin Distributors, LLC. Member FINRA/SIPC. Franklin Distributors, LLC and Franklin Templeton Investment Solutions are Franklin Templeton companies. CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute. Source: FactSet. Important data provider notices and terms available at www.franklintempletondatasources.com. a. Gross expenses are the fund's total annual operating expenses as of the fund's prospectus available at the time of publication. Actual expenses may be higher and may impact portfolio returns. Net expenses reflect contractual fee waivers, expense caps and/or reimbursements, which cannot be terminated prior to 12/31/2025 without Board consent. Additional amounts may be voluntarily waived and/or reimbursed and may be modified or discontinued at any time without notice. © 2024 Franklin Templeton. All rights reserved. Click to enlarge Original Post Editor's Note: The summary bullets for this article were chosen by Seeking Alpha editors.Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.» Mehr auf seekingalpha.com

Novartis' CEO said on Thursday that the delayed launch of blood-cancer drug pelabresib from the takeover of Morphosys could be achieved in 2027 or later, but any approval would depend on further safety data.» Mehr auf reuters.com